Saccharomyces Boulardii Strain Dbvpg 6763
Also known as: Saccharomyces boulardii, probiotic yeast, Saccharomyces boulardii strain DBVPG 6763
Overview
Saccharomyces boulardii strain DBVPG 6763 is a non-pathogenic yeast probiotic, originally isolated from tropical fruit skins. It is widely recognized for its therapeutic applications in gastrointestinal health, particularly in preventing and treating various forms of diarrhea, such as antibiotic-associated diarrhea (AAD) and traveler's diarrhea, and as an adjunct in Helicobacter pylori eradication therapy. This specific strain is well-characterized and has been extensively studied in clinical research. Its key characteristics include remarkable resistance to gastric acidity and common antibiotics, enabling it to survive passage through the gastrointestinal tract and exert beneficial effects on the gut microbiota and mucosal immune system. The efficacy and safety of S. boulardii are supported by a substantial body of high-quality evidence, including numerous randomized controlled trials and meta-analyses.
Benefits
Saccharomyces boulardii strain DBVPG 6763 offers several evidence-based benefits for gastrointestinal health. Its primary benefit is the prevention of antibiotic-associated diarrhea (AAD), demonstrating a significant relative risk reduction of approximately 53% (RR=0.47, 95% CI: 0.35–0.63, p<0.001), with a number needed to treat (NNT) of 6 to 8 patients. This benefit is supported by high-quality systematic reviews and meta-analyses. Another significant benefit is the improvement in Helicobacter pylori eradication rates, increasing success by about 9% to 15% when combined with standard antibiotic regimens, while also reducing treatment-related adverse effects. This effect is clinically meaningful, raising eradication rates from approximately 71% to 80%, and is particularly pronounced in children. Secondary benefits include a reduction in the incidence of traveler’s diarrhea. Emerging evidence suggests potential benefits in enteral nutrition-related diarrhea, neonatal necrotizing enterocolitis (NEC), and certain inflammatory bowel conditions, though these areas require further robust research. Benefits in diarrhea prevention typically manifest during or shortly after antibiotic treatment, while H. pylori eradication improvements are observed at 4 weeks post-therapy.
How it works
Saccharomyces boulardii strain DBVPG 6763 exerts its beneficial effects through multiple mechanisms within the gut. As a yeast, it is naturally resistant to gastric acid and antibiotics, allowing it to survive transit and remain active in the intestinal lumen. It modulates the gut microbiota by inhibiting the growth of pathogenic bacteria and promoting a healthier microbial balance. The strain enhances mucosal immune responses, notably by increasing the production of secretory IgA, which is crucial for gut defense. Furthermore, S. boulardii produces proteases that can degrade bacterial toxins, such as those from Clostridium difficile, thereby neutralizing their harmful effects. It also contributes to improving intestinal barrier function and reducing inflammation, supporting overall gut integrity and health. Its molecular targets include various bacterial toxins and host immune signaling pathways, contributing to its broad therapeutic actions.
Side effects
Saccharomyces boulardii is generally considered safe for the majority of the population, including children and adults. Common side effects, occurring in less than 5% of users, are typically mild gastrointestinal symptoms such as bloating or gas, which are infrequent and transient. Uncommon side effects (1-5%) include rare cases of fungemia, which have been reported almost exclusively in severely immunocompromised patients, critically ill individuals, or those with central venous catheters. Systemic infections are very rare (<1%) and are predominantly limited to these high-risk groups. Due to its yeast nature, S. boulardii has minimal drug interactions; however, caution is advised when co-administering with antifungal agents, as these could reduce its efficacy. Contraindications for use include individuals who are immunocompromised (e.g., HIV/AIDS, organ transplant recipients, those on immunosuppressive drugs), patients with central venous catheters, and those with severe underlying illnesses, due to the heightened risk of fungemia. In these populations, use should be avoided or strictly supervised by a medical professional.
Dosage
The minimum effective dose for Saccharomyces boulardii strain DBVPG 6763 typically ranges from 250–500 mg per day, which corresponds to approximately 5–10 billion Colony Forming Units (CFU) daily. This range is considered standard for most indications, including the prevention of antibiotic-associated diarrhea and as an adjunct for H. pylori eradication. Doses up to 20 billion CFU/day have been safely used in clinical trials, and there is no well-defined upper limit for safety in healthy individuals. For optimal efficacy, S. boulardii is usually administered concurrently with antibiotics or during episodes of diarrhea. It is available in various forms such as capsules, sachets, or powders, and the formulation should ensure the viability of the yeast. As a probiotic, it acts locally in the gut and is not absorbed systemically. While no specific cofactors are required, taking probiotics with food may help buffer stomach acid and enhance survival, though S. boulardii is notably acid-resistant.
FAQs
Is S. boulardii safe during antibiotic use?
Yes, S. boulardii is resistant to antibiotics and is often recommended to be taken concurrently to prevent antibiotic-associated diarrhea.
How soon can benefits be expected?
Benefits for diarrhea prevention typically occur during antibiotic treatment, while improvements in H. pylori eradication are assessed weeks after therapy completion.
Can it be used in children?
Yes, S. boulardii has demonstrated efficacy and safety in children, particularly for treating diarrhea and supporting H. pylori eradication.
Does it replace antibiotics?
No, S. boulardii is an adjunct therapy intended to complement standard treatments, not to replace antibiotics or other prescribed medications.
Research Sources
- https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1441185/full – This meta-analysis of 18 RCTs found that S. boulardii significantly increased H. pylori eradication rates by 9-15% and reduced adverse effects when used as an adjunct to standard therapy. It included both adult and pediatric populations, highlighting its broad applicability and high quality of evidence.
- https://pubmed.ncbi.nlm.nih.gov/20458757/ – This systematic review and meta-analysis, including 31 RCTs with over 5000 patients, demonstrated a significant reduction in the risk of antibiotic-associated diarrhea (RR=0.47) with S. boulardii. It confirmed a strong safety profile and high quality of evidence for this indication.
- https://www.florastor.ca/en/healthcare-professionals/florastor-11-meta-analysis-explained.html – This source references a meta-analysis that supports the efficacy of S. boulardii in improving H. pylori eradication rates and reducing adverse effects of antibiotic therapy. It highlights the clinical significance of these findings for patient management.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2868213/ – This article, likely a review or meta-analysis, provides evidence for the effectiveness of S. boulardii in preventing antibiotic-associated diarrhea. It supports the finding of a significant relative risk reduction and discusses the safety profile of the probiotic.
Supplements Containing Saccharomyces Boulardii Strain Dbvpg 6763
Recommended Articles
Top Digestive Health Ingredients
Dietary fiber, probiotics, and natural ingredients like ginger and peppermint oil are essential for improving digestive health.
Probiotics & Antibiotic Diarrhea: Meta-Analysis Insights
Meta-analyses show strong support for probiotics in reducing the risk of antibiotic-associated diarrhea, especially with certain strains.
Best Time to Take Probiotics with Antibiotics
Wait 2-3 hours after antibiotics to take probiotics to avoid reducing their effectiveness.
Probiotics for Antibiotic Diarrhea: Effectiveness & Strains
Probiotics, particularly Lactobacillus rhamnosus GG and Saccharomyces boulardii, are effective in preventing antibiotic-associated diarrhea in adults.